Exosome liquid biopsy for colorectal cancer spread
Part of Cancer, Digestive system clinical trials.
This study uses a blood test to detect if colorectal cancer that has spread to the liver has also spread to other parts of the body. It may help doctors better understand how the cancer is moving and guide treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with colorectal cancer that has spread to other parts of the body (metastatic).
- You have a blood sample taken before starting treatment for this study.
- You agree to participate and sign a consent form.
- Your medical records and scans are detailed enough to know if the cancer has spread beyond the liver.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a “liver-first” approach for colorectal cancer that has spread mainly to the liver, to see if it can help more people have the tumor(s) removed or treated. You may be eligible if your liver involvement is too extensive for immediate surgery but could become treatable after a specific plan.
This study looks at a new blood test that may help doctors better understand how far colon cancer has spread. By testing a sample of your blood (taken before surgery), researchers hope to find patterns that predict the stage of cancer and help guide treatment decisions.
This study looks at whether a substance in your blood (called PRDX1, found in tiny particles called exosomes) can help predict if colon cancer will spread to the liver after surgery. It may help doctors understand who needs more monitoring or treatment.
This study uses a simple blood test (liquid biopsy) to look for tiny bits of cancer DNA after surgery for colorectal cancer that spread to the liver. It aims to see if this test can find cancer earlier than standard scans, which may help guide future treatment decisions.
This Phase 3 trial tests a treatment approach for colorectal cancer that cannot be removed with surgery at first but has spread only to the liver. It is intended for people whose tumor is RAS/BRAF “wild-type” and who are well enough to do daily activities, to see if the treatment can control the cancer better.
This study tests whether a simple blood test can track how well your colorectal cancer is responding to first-line chemotherapy. By monitoring cancer markers in your blood, doctors may be able to detect treatment changes earlier than traditional imaging.
Hear when a new Colorectal Cancer Liver Metastases (CRLM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.